CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026
Rhea-AI Summary
CapsoVision (NASDAQ: CV) announced it will release its second quarter 2026 financial results on Thursday, August 13, 2026, after the market close. On the same day, the company will host a conference call and live webcast at 1:30 pm PT / 4:30 pm ET to discuss results and provide a corporate update. Investors can join by dialing the provided US numbers with conference ID 9178774, or via the live and archived webcast available on the Events page of the Investor Relations section of CapsoVision’s website.
Positive
- None.
Negative
- None.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 30 | First-quarter earnings date | Neutral | +5.9% | Announced May 14 release date and conference call for first-quarter results |
| Mar 12 | Full-year earnings date | Neutral | +3.0% | Announced March 26 release date and webcast for fourth-quarter results |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The two prior earnings-date announcements both preceded positive 24-hour reactions, while the broader earnings history included a negative reaction to reported results.
Key Terms
capsule endoscopy medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SARATOGA, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the Company will release second quarter 2026 financial results on Thursday, August 13, 2026, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update.
Investors interested in listening to the conference call may do so by dialing (800) 715-9871 or (646) 307-1963 and referencing conference ID 9178774. The live and archived webcast of the conference call can be found on the Events page in the Investor Relations section of CapsoVision’s website.
About CapsoVision
CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and screening of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company’s next pipeline product, CapsoCam Colon™ with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit www.capsovision.com.
Investor Relations Contact
Leigh Salvo
New Street Investor Relations
Investors@CapsoVision.com
Media Contact
Leslie Strickler and Paul Spicer
Être Communications
leslies@etrecommunications.com | (804) 240-0807
pauls@etrecommunications.com | (804) 503-9231
